Convertible therapy for unresectable colorectal liver metastases        ZHU De-xiang, REN Li, XU Jian-min. Department of General Surgery, Zhongshan Hospital, Fudan University; Institute of General Surgery, Fudan University; Colorectal Cancer Research Center, Fudan University, Shanghai 200032, China
Corresponding author：XU Jian-min, E-mail：xujmin@aliyun.com
Abstract    Surgery is the most effective and the only potentially curative treatment for colorectal liver metastases (CRLM). However, most patients with CRLM are not suitable for liver resection. In recent years, a variety of cytotoxic drugs and/or targeted drugs were used to shrink unresectable liver metastases, and some patients were converted to resectable. Thereby they might be cured following surgical resection. Therefore the purpose of convertible chemothrapy is to get the best response rate, not the maximum response rate. It should choose efficient convertible chemotherapy with short courses for preoperative chemotherapy. For KRAS wild-type patients, cetuximab combined with FOLFOX/FOLFIRI, in which 5-fluorouracil is continuous infused, is recommended, and for KRAS-mutant patients, bevacizumab combined with two-drug chemotherapy regimen or three-drug chemotherapy regimen is considered. They should be operated as soon as the metastases become resectable.